BRUSSELS — Grayling’s managing director of public affairs in Brussels, Victoria Breck, has moved in-house, taking the role of EU government affairs lead at global pharmaceutical company Novo Nordisk.

Breck had been at Grayling for more than a decade, joining as an account executive in 2009 and working up to public affairs MD, a role she has held since 2016. She started work at the Danish-headquartered pharma at the start of this month.

Grayling Brussels CEO Russell Patten told the Holmes Report: “In 10 years, Victoria went from intern to MD of the PA department, having diligently worked her way up the ladder in a company that prioritises meritocracy and personal development. Vic has been a hard-working and loyal partner who will remain a true friend to all of us – colleagues and clients – who have had the pleasure of working with her. We wish her every success in her new endeavours.”

Europe, UK & Ireland CEO Sarah Scholefield added: “Victoria has played a huge part in Grayling’s success, both in Brussels and across our international network. We are truly sorry to see her go but wish her all the very best in the next phase of her career.”

In a LinkedIn post Breck, whose specialist area is international and EU advocacy in the fields of healthcare, food and consumer policy, said: “When I started my career, I would have never imagined staying with one employer for almost 11 years, but Grayling was no ordinary place. Grayling has given me amazing opportunities to learn, grow and develop as a professional, surrounded by wonderful colleagues, and working with challenging clients on exciting projects.”

Of her new venture, she said: “I am delighted to be leading Novo Nordisk's engagement efforts in Brussels, working on topics that are close to my heart.”

Novo Nordisk’s treatment and research areas include diabetes, obesity, liver disease, haemophilia and growth disorders.